ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

15 12 2023 17:11:43 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 12 2023 22:00:49 提供 Nasdaq GlobeNewswire

FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

29 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

03 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 11 2023 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Report Third Quarter 2023 Financial Results

25 10 2023 16:00:00 提供 Nasdaq GlobeNewswire

New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials

20 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Pricing of $100 Million Public Offering

19 10 2023 23:45:47 提供 Nasdaq GlobeNewswire

Arcutis Announces Proposed Public Offering

19 10 2023 16:04:44 提供 Nasdaq GlobeNewswire

Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

13 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

06 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 10 2023 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

27 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis

25 9 2023 09:00:47 提供 Nasdaq GlobeNewswire

Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

19 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 9 2023 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

12 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)

07 9 2023 08:15:50 提供 Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

05 9 2023 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report

31 8 2023 08:00:00 提供 Nasdaq GlobeNewswire